convers
ribavirin
monophosph
adenosin
kinas
ratelimit
step
activ
broad
spectrum
antivir
drug
variat
seri
bioisoster
homolog
mark
effect
activ
human
adenosin
kinas
analysi
comput
descriptor
bind
model
offer
insight
design
novel
substrat
rna
virus
signific
pathogen
caus
ill
rang
common
cold
epidem
scale
diseas
aid
hepat
c
influenza
emerg
diseas
caus
agent
yellow
fever
viru
west
nile
viru
dengu
viru
sar
cov
hantavirus
antivir
drug
avail
clinic
treatment
must
confront
divers
rapid
evolut
resist
strain
antivir
drug
ribavirin
first
synthes
shown
broad
spectrum
antivir
activ
rna
dna
virus
ribavirin
use
clinic
combin
interferona
treatment
hepat
c
viru
hcv
infect
respiratori
syncyti
viru
rsv
sever
viral
hemorrhag
fever
caus
virus
recent
sar
cov
infect
side
effect
includ
hemolyt
anemia
viral
resist
major
limit
phosphoryl
ribavirin
monophosph
human
adenosin
kinas
hadk
ratelimit
step
activ
physiolog
relev
triphosph
sever
mechan
ribavirin
antivir
activ
identifi
inhibit
inosin
monophosph
dehydrogenas
decreas
intracellular
guanosin
triphosph
gtp
concentr
predomin
mechan
antivir
activ
ribavirin
yellow
fever
parainfluenza
respiratori
syncyti
virus
mechan
ribavirin
antivir
activ
includ
inhibit
influenza
viru
rna
polymeras
vitro
ribavirin
triphosph
rtp
inhibit
viral
genom
cap
interfer
guanyltransferas
methyltransferas
activ
sindbi
viru
modul
host
immun
respons
hcv
infect
patient
recent
interest
focus
increas
mutat
rate
viral
genom
affect
replic
transcript
virion
viabil
shown
case
hantaan
viru
old
world
hantaviru
produc
lifethreaten
hemorrhag
fever
renal
syndrom
great
interest
develop
synthet
nucleosid
analog
modifi
hydrogen
bond
pstack
hydrophob
steric
featur
exploit
decreas
fidel
viral
replic
transcript
consid
import
hadk
metabol
activ
interest
evalu
structur
effect
within
close
relat
seri
part
ongo
effort
develop
new
antivir
drug
rna
virus
identifi
seri
triazol
deriv
provid
modifi
steric
volum
lipophil
hydrogenbond
capac
ionic
charg
compound
possess
isoster
substitut
includ
nitro
keton
carboxyl
group
respect
deriv
homolog
constitut
isom
incorpor
addit
methylen
group
carbonyl
oxygen
replac
nmethyl
amidin
deriv
nitro
deriv
prepar
direct
fusion
dribofuranos
carboxyl
nmethylcarboxamid
obtain
deprotect
commerci
avail
methyl
ester
follow
saponif
methylamin
substitut
respect
methyl
keton
acetamid
synthes
shown
scheme
introduct
tertbutyldimethylsilyl
protect
group
follow
select
reduct
methyl
ester
diisobutylaluminum
hydrid
provid
aldehyd
addit
methylmagnesium
bromid
oxid
pyridinium
chlorochrom
deprotect
gave
methyl
keton
acetamid
synthes
reduct
nitro
hydrazin
follow
acetyl
ester
hydrolysi
nmethylamidin
methyl
imid
prepar
follow
literatur
rout
hydrolysi
evid
h
nmr
two
week
hadk
clone
gener
provid
dr
jozef
spychala
unc
chapel
hill
chapel
hill
nc
hadk
prepar
describ
nucleosid
assay
substrat
hadk
reaction
product
detect
hplc
assay
condit
consist
mm
hepe
ph
mm
kcl
mm
mgcl
mm
atp
bsa
lm
deoxycoformycin
lm
test
compound
enzym
reaction
start
addit
enzym
incub
water
bath
aliquot
taken
interv
reaction
stop
addit
perchlor
acid
sampl
neutral
ph
precipit
salt
remov
centrifug
reactant
product
separ
hplc
use
bio
basic
anion
exchang
column
thermo
electron
corp
bellefont
pa
linear
salt
ph
gradient
mm
ammonium
phosphat
ph
mm
ammonium
phosphat
ph
peak
detect
elut
column
absorb
k
max
typic
nm
enzym
reaction
linear
incub
period
substrat
convers
maintain
less
potenti
inhibit
hadk
activ
evalu
monitor
format
ribavirin
monophosph
presenc
compound
initi
ribavirin
concentr
lm
individu
compound
lm
specif
rel
activ
phosphoryl
hadk
shown
tabl
enzym
activ
detect
four
ribavirin
analog
howev
analog
less
effect
substrat
addit
none
ribavirin
analog
inhibit
phosphoryl
ribavirin
hadk
data
shown
sinc
excess
compound
inhibit
phosphoryl
ribavirin
result
indic
k
analog
much
higher
k
ribavirin
compound
activ
ribavirin
inhibit
phosphoryl
ribavirin
result
would
suggest
higher
v
max
ribavirin
comput
method
use
character
possibl
structur
contribut
hadk
activ
within
seri
geometri
fulli
optim
ga
phase
level
theori
case
comput
identifi
syn
glycosid
conform
compound
minimum
energi
conform
triazol
base
orient
ribofuranos
ring
result
consist
report
conform
prefer
solut
determin
nmr
circular
dichroism
valid
calcul
glycosid
conform
confirm
experiment
observ
strong
noe
correl
noesi
spectrum
comput
deriv
molecular
descriptor
shown
use
compar
evalu
bioisoster
electrostat
potenti
densiti
map
van
der
waal
surfac
space
fill
model
use
molecular
electrostat
potenti
mep
map
isodens
surfac
molecul
provid
visual
indic
qualit
comparison
hydrogen
bond
capac
spectrum
rang
red
repres
high
electron
densiti
blue
tabl
addit
select
comput
descriptor
list
tabl
hydrophob
interact
approxim
use
complementari
lipophil
profil
water
access
hydrophob
surfac
area
molecul
cpk
area
log
p
octanolwat
partit
coeffici
log
p
ow
comparison
longrang
electrostat
interact
neutral
molecul
approxim
use
dipol
momentvolum
lv
descriptor
chemic
hard
g
lumo
provid
estim
aromat
relat
propens
pstack
calcul
g
valu
compound
similar
ev
repres
compar
pstack
capac
across
seri
substitut
triazol
base
compound
evalu
fall
within
two
gener
class
isoster
possess
overal
steric
volum
similar
alter
function
affect
hbond
homolog
analog
possess
increas
steric
profil
alter
hydrophob
deriv
activ
synthet
analog
compound
possess
molecular
electrostat
potenti
map
similar
ribavirin
smallest
volum
highest
lipophil
dipol
momentvolum
nitro
group
isostructur
carboxamid
typic
exhibit
weaker
intermolecular
hbond
accept
capabl
nitrat
base
analog
extens
evalu
potenti
univers
base
nitroaren
typic
form
strong
pp
stack
interact
polar
hetero
aryl
ring
deriv
report
undergo
phosphoryl
equival
ribavirin
use
hamster
adk
keton
structur
mimic
replac
amin
methyl
elimin
two
hbond
donor
activ
nmethyl
deriv
compar
nmethylribamidin
less
activ
ineffect
substrat
manual
dock
calcul
minimum
energi
conform
ribavirin
hadk
substrat
bind
site
reveal
possibl
deeper
penetr
lipophil
pocket
enabl
pstack
triazol
phenylalanin
residu
posit
carboxamid
amin
group
mimic
critic
adenosin
undergo
hbond
bound
water
associ
residu
increas
penetr
substrat
bind
pocket
would
posit
hydroxi
group
bound
atp
respons
phosphoryl
result
reduc
rate
phosphoryl
rel
adenosin
less
effici
hadk
substrat
compar
pstack
capac
expect
across
seri
base
comput
gvalu
nitro
methyl
group
interact
hbond
donor
methyl
carboxamid
would
effect
interact
alter
substrat
orient
enzym
structur
compar
adenosin
result
decreas
activ
instruct
compar
result
structur
modifi
nucleosid
deriv
substrat
hadk
fig
tubercidin
relat
deriv
sangivamycin
exhibit
favor
electrostat
pstack
interact
excel
substrat
adk
contrast
analog
toyocomycin
tubercidin
potent
adk
inhibitor
due
displac
result
stronger
hydrophob
interact
studi
demonstr
structur
modif
significantli
affect
hadk
activ
ribavirin
deriv
ineffect
substrat
hadk
result
may
correl
report
lack
antivir
activ
distinct
virus
although
metabol
enzymat
pathway
exclud
isoster
deriv
nmethyl
homolog
phosphoryl
hadk
antivir
activ
compound
current
investig
consider
comput
descriptor
structur
interact
provid
insight
substrat
bind
activ
provid
direct
addit
structur
optim
develop
antivir
nucleosid
analog
improv
select
reduc
side
effect
